Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Wahid Hanna"'
Autor:
Bayard L. Powell, Kieron Dunleavy, Michelle A. Fanale, Philip J. Bierman, David Peace, Andrea Nicole Lucas, Jeremy S. Abramson, Wyndham H. Wilson, Christopher Melani, Stefania Pittaluga, Peter R. Watson, Seth M. Steinberg, Wahid Hanna, Brad S. Kahl, Elaine S. Jaffe, Mark Roschewski, Brian K. Link, Nancy L. Bartlett, Richard F. Little, Ariela Noy, Deepa Jagadeesh, Jonathan W. Friedberg, Prapti A. Patel, Ronald T. Mitsuyasu
Publikováno v:
J Clin Oncol
PURPOSE Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyc
Autor:
Maen A. Hussein, Raid Aljumaily, Shannon R. Morris, Bojan Zaric, Wahid Hanna, Didier Verhoeven, Z. Andric, Jie Xiao, J. Thaddeus Beck, Janakiraman Subramanian, Renata Ferrarotto, Joyce M Antal, Davorin Radosavljevic, Lowell L. Hart, Taofeek K. Owonikoko
Publikováno v:
Advances in therapy
Advances in Therapy
Advances in Therapy
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Tril
Autor:
Rajesh K. Malik, Petros Nikolinakos, Ralph V. Boccia, Konstantin H. Dragnev, Shannon R. Morris, Robert Hoyer, Donald A. Richards, Taofeek K. Owonikoko, A. Lowczak, Patrick J. Roberts, Vi Kien Chiu, J.T. Beck, Tibor Csoszi, Raid Aljumaily, Lowell L. Hart, I. Bulat, Maen A. Hussein, P. Sawrycki, Jessica A. Sorrentino, M. Maglakelidze, C.M. Rocha Lima, S. Adler, Jared Weiss, Zhao Yang, Joyce M Antal, S.R. Schuster, Wahid Hanna, M. Domine Gomez, Anne Y. Lai, John T. Hamm
Publikováno v:
Annals of Oncology
Background Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function duri
Autor:
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson, Jian Campian, Lawrence Recht, Samuel Goldlust, Kevin Becker, Gene Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris Groves, Santosh Kesari, Zsolt Horvath, Ryan Merrell, Richard Curry, James O'Rourke, David Schuster, Maciej Mrugala, Randy Jensen, John Trusheim, Glenn Lesser, Karl Belanger, Andrew Sloan, Benjamin Purow, Karen Fink, Jeffrey Raizer, Michael Schulder, Suresh Nair, Scott Peak, Alba Brandes, Nimish Mohile, Joseph Landolfi, Jon Olson, Ross Jennens, Paul DeSouza, Bridget Robinson, Marka Crittenden, Kent Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas Hadjipanayis, Pierre Giglio, Frank Mott, David Mathieu, Nathalie Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela Bota, Maciej Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid Thompson, Lawrence Berk, John McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah Blumenthal, Sá Barreto Costa Marcos André de, Anna Nowak, Nimit Singhal, Andreas Hottinger, Andrea Schmid, Gordan Srkalovic, David Baskin, Camilo Fadul, Louis Nabors, Renato LaRocca, John Villano, Nina Paleologos, Petr Kavan, Marshall Pitz, Brian Thiessen, Ahmed Idbaih, Jean Sébastien Frenel, Julien Domont, Oliver Grauer, Peter Hau, Christine Marosi, Jan Sroubek, Elizabeth Hovey, P.S. Sridhar, Lawrence Cher, Erin Dunbar, Thomas Coyle, Jane Raymond, Kevin Barton, Michael Guarino, Sumul Raval, Baldassarre Stea, Jorge Dietrich, Kirsten Hopkins, Sara Erridge, Joachim-Peter Steinbach, Losada Estela Pineda, Quintero Carmen Balana, Barco Berron Sonia del, Miklós Wenczl, Katalin Molnár, Katalin Hideghéty, Alexander Lossos, Linde Myra van, Ana Levy, Rosemary Harrup, William Patterson, Zarnie Lwin, Sith Sathornsumetee, E-Jian Lee, Jih-Tsun Ho, Steven Emmons, J. Paul Duic, Spencer Shao, Hani Ashamalla, Michael Weaver, Jose Lutzky, Nicholas Avgeropoulos, Wahid Hanna, Mukund Nadipuram, Gary Cecchi, Robert O'Donnell, Susan Pannullo, Jennifer Carney, Mark Hamilton, Mary MacNeil, Ronald Beaney, Michel Fabbro, Oliver Schnell, Rainer Fietkau, Guenther Stockhammer, Bela Malinova, Karel Odrazka, Martin Sames, Gil Miguel Gil, Evangelia Razis, Konstantin Lavrenkov, Guillermo Castro, Francisco Ramirez, Clarissa Baldotto, Fabiana Viola, Suzana Malheiros, Jason Lickliter, Stanislaw Gauden, Arunee Dechaphunkul, Iyavut Thaipisuttikul, Ziad Thotathil, Hsin-I Ma, Wen-Yu Cheng, Chin-Hong Chang, Fernando Salas, Pierre-Yves Dietrich, Christoph Mamot, Lakshmi Nayak, Shona Nag
Publikováno v:
The Lancet Oncology, Vol. 18, No 10 (2017) pp. 1373-1385
The Lancet. Oncology, vol 18, iss 10
The Lancet. Oncology, vol 18, iss 10
Summary Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6b5ae20a38597b1d233965368e0708
https://doi.org/10.5167/uzh-141081
https://doi.org/10.5167/uzh-141081
Autor:
Jonathan W. Friedberg, Brad S. Kahl, Brian K. Link, Bayard L. Powell, Mark Roschewski, Christopher Melani, Wyndham H. Wilson, Deepa Jagadeesh, Ariela Noy, Wahid Hanna, Nancy L. Bartlett, Seth M. Steinberg, David Peace, Jeremy S. Abramson, Kieron Dunleavy, Michelle A. Fanale, Philip J. Bierman, Andrea Nicole Lucas, Samir Parekh, Richard F. Little, Peter R. Watson
Publikováno v:
Hematological Oncology. 35:133-134
Publikováno v:
Journal of Nuclear Medicine. 48:744-751
PET and 18F-FDG have the potential to follow the early metabolic response to chemotherapy in patients with non–small cell lung cancer and to predict success or failure of the therapy. Methods: We studied 16 patients with non–small cell lung cance
Autor:
Bruce M. Ewenstein, Richard S. Schwartz, John J. Byrnes, Juan Chediak, Wahid Hanna, Pier Mannuccio Mannucci, Marlies Ledford, Anastassios D. Retzios, Craig M. Kessler, Barbara A. Kapelan
Publikováno v:
Blood. 99:450-456
Among patients with von Willebrand disease (VWD) who are unresponsive to desmopressin therapy, replacement with plasma-derived concentrates is the treatment of choice. Because prospective studies are lacking, such treatment has been largely empirical
Autor:
Sameh Mikhail, B. O’Neil, Wahid Hanna, A Neki, C.J. Li, Kristen K. Ciombor, Alexander Starodub, S Shahda, Anne M. Noonan, Bassel F. El-Rayes, Wei Li, T. S. Bekaii-Saab, Laura Borodyansky, Youzhi Li, Walid L. Shaib, A Sehdev, C. Oh
Publikováno v:
Annals of Oncology. 28:iii150
Autor:
Alexander Starodub, Amikar Sehdev, Chiang Li, Walid L. Shaib, Wahid Hanna, Kristen K. Ciombor, Laura Borodyansky, Sameh Mikhail, Bassel F. El-Rayes, Wei Li, Safi Shahda, Youzhi Li, Anterpreet S. Neki, Tanios Bekaii-Saab, Cindy Oh, Anne M. Noonan, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology. 35:4106-4106
4106 Background: Cancer stem cells are fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified by its ability to inhibit STAT3-driven gene trans
Autor:
Chien-Shing Chen, Rachel Neuwirth, Wahid Hanna, Fernando Cabanillas, Michael Craig, Owen A. O'Connor, Dixie-Lee Esseltine
Publikováno v:
British journal of haematology. 166(6)
Summary This non-comparative phase II study (ClinicalTrials.gov: NCT00715208) evaluated bortezomib in place of vincristine in established rituximab-chemotherapy regimens in relapsed/refractory follicular (FL) or marginal zone lymphoma (MZL). Patients